News
Synthetic biology firm Persephone Biosciences, developing microbiome-based medicines for patient and infant health, closed a $15 million seed round.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback